Regeneron Pharmaceuticals Inc
REGN598.760USD
+29.850+5.25%
收盘 04/30, 16:00（美东）报价延迟15分钟
1.08B总市值
0.24市盈率 TTM
关于 Regeneron Pharmaceuticals Inc 公司
Regeneron Pharmaceuticals, Inc. 是一家综合性生物技术公司。该公司发明、开发、制造和销售用于治疗严重疾病的药物。其产品和正在开发的产品候选物旨在帮助患有眼部疾病、过敏和炎症性疾病、癌症、心血管和代谢疾病、神经系统疾病、血液病、传染病和罕见疾病的患者。该公司通过其 VelociSuite 技术（例如 VelocImmune，它使用基因人源化小鼠生产优化的全人抗体和双特异性抗体）以及通过 Regeneron Genetics Center 等雄心勃勃的研究计划，帮助加速和改进传统的药物开发流程。其上市产品包括 EYLEA（阿柏西普）注射液；Dupixent（dupilumab）注射液；Libtayo（cemiplimab）注射液；Praluent（alirocumab）注射液；Kevzara（sarilumab）注射液等。
公司简介
公司代码REGN
公司名称Regeneron Pharmaceuticals Inc
上市日期Apr 02, 1991
成立日期1988
CEODr. Leonard S. Schleifer, M.D., Ph.D
员工数量15106
证券类型Ordinary Share
年结日Apr 02
公司地址777 Old Saw Mill River Road
城市TARRYTOWN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编10591
电话17813705000
网址https://www.regeneron.com/
公司代码REGN
上市日期Apr 02, 1991
成立日期1988
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Neil Stahl, Ph.D.
Dr. Neil Stahl, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
54.50K
-1.39%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
53.42K
+0.05%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.92K
+0.07%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Senior Vice President - Finance
Chief Financial Officer, Senior Vice President - Finance
19.75K
+20.78%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.66K
-0.10%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.37K
+9.94%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Neil Stahl, Ph.D.
Dr. Neil Stahl, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
54.50K
-1.39%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
53.42K
+0.05%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.00K
+2.78%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.92K
+0.07%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
EYLEA
4.77B
33.57%
Sanofi
4.53B
31.91%
Bayer
1.50B
10.55%
EYLEA HD
1.20B
8.46%
Libtayo
787.30M
5.54%
Other
1.42B
9.97%
暂无数据
业务
地区
业务USD
名称
营收
占比
EYLEA
4.77B
33.57%
Sanofi
4.53B
31.91%
Bayer
1.50B
10.55%
EYLEA HD
1.20B
8.46%
Libtayo
787.30M
5.54%
Other
1.42B
9.97%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
8.59%
Fidelity Management & Research Company LLC
7.41%
BlackRock Institutional Trust Company, N.A.
5.30%
JP Morgan Asset Management
4.88%
State Street Global Advisors (US)
4.49%
Other
69.32%
持股股东
股东统计
占比
The Vanguard Group, Inc.
8.59%
Fidelity Management & Research Company LLC
7.41%
BlackRock Institutional Trust Company, N.A.
5.30%
JP Morgan Asset Management
4.88%
State Street Global Advisors (US)
4.49%
Other
69.32%
股东类型
股东统计
占比
Investment Advisor
47.91%
Investment Advisor/Hedge Fund
32.96%
Research Firm
2.77%
Pension Fund
2.68%
Bank and Trust
2.14%
Hedge Fund
2.07%
Individual Investor
1.94%
Sovereign Wealth Fund
1.15%
Insurance Company
0.08%
Other
6.29%
机构持股
更新时间: 1月19日 周日
更新时间: 1月19日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q1
2549
100.69M
94.82%
-69.63K
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
2023Q1
2366
99.66M
92.70%
-1.10M
2022Q4
2333
99.78M
93.16%
-1.62M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
9.24M
8.59%
-32.55K
-0.35%
Dec 31, 2024
Fidelity Management & Research Company LLC
7.97M
7.41%
-2.08M
-20.68%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.70M
5.3%
+193.71K
+3.52%
Dec 31, 2024
JP Morgan Asset Management
5.24M
4.88%
-524.97K
-9.10%
Dec 31, 2024
State Street Global Advisors (US)
4.83M
4.49%
-70.17K
-1.43%
Dec 31, 2024
Capital International Investors
4.74M
4.41%
+1.39M
+41.55%
Dec 31, 2024
Capital World Investors
2.78M
2.58%
-1.52M
-35.35%
Dec 31, 2024
Geode Capital Management, L.L.C.
2.43M
2.26%
+155.37K
+6.84%
Dec 31, 2024
Dodge & Cox
2.32M
2.16%
+9.38K
+0.41%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
2.24M
2.08%
+29.93K
+1.36%
Feb 28, 2025
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Tema Neuroscience and Mental Health ETF
7.56%
Invesco Nasdaq Biotechnology ETF
7.22%
ProShares Ultra Nasdaq Biotechnology
6.8%
Simplify Health Care ETF
6.73%
iShares Biotechnology ETF
6.22%
VanEck Biotech ETF
4.94%
Invesco Biotechnology & Genome ETF
4.65%
iShares Genomics Immunology and Healthcare ETF
4%
Franklin Genomic Advancements ETF
3.51%
Invesco QQQ Low Volatility ETF
3.35%
查看更多
Tema Neuroscience and Mental Health ETF
占比7.56%
Invesco Nasdaq Biotechnology ETF
占比7.22%
ProShares Ultra Nasdaq Biotechnology
占比6.8%
Simplify Health Care ETF
占比6.73%
iShares Biotechnology ETF
占比6.22%
VanEck Biotech ETF
占比4.94%
Invesco Biotechnology & Genome ETF
占比4.65%
iShares Genomics Immunology and Healthcare ETF
占比4%
Franklin Genomic Advancements ETF
占比3.51%
Invesco QQQ Low Volatility ETF
占比3.35%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据